GLOD5

Across TCGA pan-cancer cohorts, GLOD5 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GLOD5 data layer compared with 18 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GLOD5 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GLOD5 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where GLOD5 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	III,IV	0.985	0.237	.017	8	view →
PDAC	DFS	Quartile	II,III,IV	0.272	0.737	.017	3	view →
LSCC	DFS	Median	II,III,IV	1.000	0.598	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GLOD5–CCRCC (OS)

Open the CCRCC breakdown →